SYNkinase Pty. Ltd. is a company located in Melbourne, Shanghai, Suzhou, San Diego, and Cambridge that develops inhibitors targeting various proteins in the MAP Kinase signaling pathway. The document lists over 30 inhibitor compounds available from SYNkinase that target nodes in the pathway including MEK, ERK, JNK, p38, and Raf. Adipogen International is also listed as developing compounds targeting this important cell signaling cascade.